New trial aims to boost survival in kidney cancer by combining radiation with drug therapy

NCT ID NCT06726421

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase III trial is testing whether adding a precise type of radiation (SBRT) to standard drug therapy (targeted drugs and/or immunotherapy) can help people with kidney cancer that has spread to up to five spots live longer without the disease getting worse. The study will enroll 252 participants and compare the combination approach to drug therapy alone. Researchers will also track side effects and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic body radiotherapy (SBRT) plus standard systemic therapy (targeted drugs and/or immunotherapy)
What this could lead to: If it works, this could show that adding precise radiation to standard drugs helps people with limited kidney cancer spread live longer without progression.
What could go wrong: This is an early-stage Phase III trial with 252 participants, so results may not apply to everyone. Adding radiation may increase side effects without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY CANCER METASTATIC RENAL CELL CARCINOMA (KIDNEY CANCER) RENAL CELL CARCINOMA, METASTATIC

Contacts and locations

Locations

Cancer Hospital, Chinese Academy of Medical Sciences
NOT_YET_RECRUITING

Beijing, 100021, China
Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, 200032, China
Peking University First Hospital
RECRUITING

Beijing, 100034, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
The First Affiliated Hospital of Wenzhou Medical University
RECRUITING

Wenzhou, Zhejiang, China
The First Hospital of Jilin University
RECRUITING

Changchun, Jilin, China
Union Hospital, Fujian Medical University
RECRUITING

Fuzhou, Fujian, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China
West China Hospital, Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.